Using Targeted Virotherapy to Treat a Resistant Ewing Sarcoma Model: From the Bedside to the Bench and Back

Figure 7

VSVΔM51 treatment significantly reduces tumor growth after local and systemic administration. (a)-(b) A single VSVΔM51 injection was administered either intravenously (I.V.) (a) or intratumoral (I.T.) (b). Tumor size was monitored over a period of time. Mice were sacrificed based on a preset tumor volume decided upon with animal care. Error bars represent standard error of the mean ^∗𝑃<0.05, ^∗∗𝑃<0.005 (Student’s t-test). 𝑁=4 mice per group. Note VSV in legend represents VSVΔM51.

(a)

(b)